1. Home
  2. BSET vs MDXH Comparison

BSET vs MDXH Comparison

Compare BSET & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bassett Furniture Industries Incorporated

BSET

Bassett Furniture Industries Incorporated

N/A

Current Price

$14.00

Market Cap

153.2M

ML Signal

N/A

Logo MDxHealth SA

MDXH

MDxHealth SA

N/A

Current Price

$3.31

Market Cap

183.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
BSET
MDXH
Founded
1902
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Home Furnishings
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
153.2M
183.4M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
BSET
MDXH
Price
$14.00
$3.31
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
23.2K
110.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
5.74%
N/A
EPS Growth
163.06
N/A
EPS
0.70
N/A
Revenue
$456,855,000.00
N/A
Revenue This Year
$4.63
$30.31
Revenue Next Year
$4.34
$18.38
P/E Ratio
$20.00
N/A
Revenue Growth
0.96
N/A
52 Week Low
$13.96
$1.36
52 Week High
$19.75
$5.33

Technical Indicators

Market Signals
Indicator
BSET
MDXH
Relative Strength Index (RSI) 36.16 42.88
Support Level N/A $3.05
Resistance Level $17.29 $3.78
Average True Range (ATR) 0.50 0.17
MACD -0.07 -0.02
Stochastic Oscillator 26.17 15.09

Price Performance

Historical Comparison
BSET
MDXH

About BSET Bassett Furniture Industries Incorporated

Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: